BR112017018649A2 - composto bicíclico de piridina - Google Patents

composto bicíclico de piridina

Info

Publication number
BR112017018649A2
BR112017018649A2 BR112017018649-7A BR112017018649A BR112017018649A2 BR 112017018649 A2 BR112017018649 A2 BR 112017018649A2 BR 112017018649 A BR112017018649 A BR 112017018649A BR 112017018649 A2 BR112017018649 A2 BR 112017018649A2
Authority
BR
Brazil
Prior art keywords
lap
avp
inventors
inhibition
amino
Prior art date
Application number
BR112017018649-7A
Other languages
English (en)
Japanese (ja)
Other versions
BR112017018649B8 (pt
BR112017018649B1 (pt
Inventor
Kawaguchi Kenichi
Ishihata Akihiro
Kanai Akira
Inagaki Yusuke
Hiramoto Masashi
Enjo Kentaro
takamatsu Hajime
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of BR112017018649A2 publication Critical patent/BR112017018649A2/pt
Publication of BR112017018649B1 publication Critical patent/BR112017018649B1/pt
Publication of BR112017018649B8 publication Critical patent/BR112017018649B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

o problema a ser resolvido pela presente invenção é fornecer um composto adequado para uma composição farmacêutica, especificamente uma composição farmacêutica para o tratamento de noctúria. os inventores têm assumido que a inibição da atividade noturna de leucina aminopeptidase placentária (p-lap), ou seja, amino-peptidase que cliva a avp, manteria e/ou aumentaria um nível endógeno de avp para aprimorar o efeito antidiurético, que contribuiria para uma diminuição do número de esvaziamentos noturnos e têm extensivamente estudado compostos que inibem a p-lap. como resultado, os inventores descobriram que os derivados de ácido (2r)-3-amino-2-(piridilmetil bicíclico)-2-hidróxi-propanoico têm excelente atividade inibitória da p-lap. os inventores têm avaliado os efeitos antidiuréticos em ratos carregados de água e descobriram que os compostos aumentam os níveis de avp endógena por inibir p-lap e consequentemente reduzem a produção de urina. a presente invenção fornece, portanto, compostos esperados por serem usados como um agente para o tratamento de noctúria baseado na inibição de p-lap.
BR112017018649A 2015-03-09 2015-11-27 Composto bicíclico de piridina BR112017018649B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-046121 2015-03-09
JP2015046121 2015-03-09
PCT/JP2015/083345 WO2016143200A1 (ja) 2015-03-09 2015-11-27 二環式ピリジン化合物

Publications (3)

Publication Number Publication Date
BR112017018649A2 true BR112017018649A2 (pt) 2018-04-17
BR112017018649B1 BR112017018649B1 (pt) 2023-07-11
BR112017018649B8 BR112017018649B8 (pt) 2023-10-03

Family

ID=56880128

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018649A BR112017018649B8 (pt) 2015-03-09 2015-11-27 Composto bicíclico de piridina

Country Status (23)

Country Link
US (1) US10023583B2 (pt)
EP (1) EP3269721B1 (pt)
JP (1) JP6646648B2 (pt)
KR (1) KR102446212B1 (pt)
CN (1) CN107428768B (pt)
AR (1) AR102849A1 (pt)
AU (1) AU2015386039B2 (pt)
BR (1) BR112017018649B8 (pt)
CA (1) CA2976746C (pt)
CO (1) CO2017008372A2 (pt)
ES (1) ES2869924T3 (pt)
IL (1) IL254307B (pt)
MX (1) MX370920B (pt)
MY (1) MY198083A (pt)
PH (1) PH12017501596B1 (pt)
PL (1) PL3269721T3 (pt)
PT (1) PT3269721T (pt)
RU (1) RU2700411C2 (pt)
SG (1) SG11201706745PA (pt)
TW (1) TWI700285B (pt)
UA (1) UA121889C2 (pt)
WO (1) WO2016143200A1 (pt)
ZA (1) ZA201706038B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020080394A1 (ja) 2018-10-16 2020-04-23 日本ケミファ株式会社 睡眠の質の改善剤
US20210393562A1 (en) 2018-10-17 2021-12-23 Nippon Chemiphar Co., Ltd. Therapeutic or prophylactic agent for nocturnal polyuria

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200702041B (en) 2004-09-09 2008-09-25 Florey Howard Inst Enzyme inhibitors and uses thereof
JP5198439B2 (ja) * 2006-06-08 2013-05-15 イーライ リリー アンド カンパニー 新規なｍｃｈ受容体アンタゴニスト
NZ585338A (en) 2007-11-19 2012-08-31 Howard Florey Inst Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
CA2741500A1 (en) 2008-11-06 2010-05-14 Astellas Pharma Inc. Carbamate compound or salt thereof
JP2013147430A (ja) * 2010-04-28 2013-08-01 Astellas Pharma Inc 夜間頻尿の予防又は治療剤
SI2615089T1 (sl) * 2010-09-07 2016-08-31 Astellas Pharma Inc. Spojine pirazolokinolina
IN2015DN00127A (pt) * 2012-07-11 2015-05-29 Nimbus Iris Inc
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
RU2683261C2 (ru) * 2014-05-28 2019-03-27 Астеллас Фарма Инк. Производное пиридина

Also Published As

Publication number Publication date
MX2017010930A (es) 2018-01-23
KR102446212B1 (ko) 2022-09-22
TW201636352A (zh) 2016-10-16
BR112017018649B8 (pt) 2023-10-03
RU2017134316A (ru) 2019-04-03
BR112017018649B1 (pt) 2023-07-11
AR102849A1 (es) 2017-03-29
AU2015386039A1 (en) 2017-08-10
UA121889C2 (uk) 2020-08-10
WO2016143200A1 (ja) 2016-09-15
US20180022755A1 (en) 2018-01-25
CA2976746A1 (en) 2016-09-15
TWI700285B (zh) 2020-08-01
MX370920B (es) 2020-01-09
PH12017501596A1 (en) 2018-02-12
RU2700411C2 (ru) 2019-09-17
JP6646648B2 (ja) 2020-02-14
ES2869924T3 (es) 2021-10-26
EP3269721A4 (en) 2018-08-01
SG11201706745PA (en) 2017-09-28
RU2017134316A3 (pt) 2019-04-24
PL3269721T3 (pl) 2021-10-11
US10023583B2 (en) 2018-07-17
KR20170124531A (ko) 2017-11-10
ZA201706038B (en) 2019-01-30
EP3269721A1 (en) 2018-01-17
PT3269721T (pt) 2021-05-05
JPWO2016143200A1 (ja) 2018-02-08
MY198083A (en) 2023-07-31
IL254307A0 (en) 2017-11-30
PH12017501596B1 (en) 2018-02-12
CO2017008372A2 (es) 2017-11-30
CA2976746C (en) 2023-01-24
CN107428768B (zh) 2020-09-18
CN107428768A (zh) 2017-12-01
IL254307B (en) 2020-11-30
AU2015386039B2 (en) 2020-05-07
EP3269721B1 (en) 2021-04-07

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12015502028A1 (en) Ido inhibitors
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112015032595A2 (pt) inibidores de ido
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
GEP20217316B (en) Aromatic sulfonamide derivatives
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201691461A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
EA202091003A1 (ru) Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
BR112013005532A2 (pt) agente terapêutico para dor
BR112017018649A2 (pt) composto bicíclico de piridina
BR112016027729A2 (pt) Composto derivado de piridina, composição farmacêutica contendo o referido composto e seu uso
EA201992793A1 (ru) Ингибиторы протеинкиназ
EA201992829A1 (ru) Карбоксильные производные в качестве ингибиторов протеинкиназ

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2015, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2740 DE 11/07/2023 QUANTO AO ENDERECO POR ERRO MATERIAL DO TITULAR.